Cost-Effectiveness Of Pembrolizumab As Second-Line Therapy For The Treatment Of Locally Advanced Or Metastatic Urothelial Carcinoma In The United States.

Yichen Zhong,Yizhen Lai,Haojie Li,Rachael Batteson,Yang Meng,Tara L. Frenkl,James Luke Godwin,Guru Sonpavde

JOURNAL OF CLINICAL ONCOLOGY（2019）

引用 0|浏览13

暂无评分

摘要

e16010Background: Pembrolizumab is approved by the US Food and Drug Administration for the treatment of locally advanced or metastatic urothelial carcinoma (mUC) following platinum-based chemothera...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要